Over all (n = 105) | <5 years (n = 17) | ≥5 to <10 years (n = 49) | ≥10 years (n = 39) | |
---|---|---|---|---|
Sex: Male (%) | 61 (58.1%) | 12 (70%) | 29 (59%) | 20(51%) |
CD4-T cell count | 530 (338–780) | 1051 (528–1154) | 586 (401–768) | 373 (251–578) |
Median (IQR*) | ||||
Viral load log copies/mL | 5.24 (4.62-5.66) | 5.56 (5.51-6.05) | 5.12 (4.55-5.55) | 5.2 (4.73-5.63) |
Median (IQR*) | ||||
WHO Clinical stage | ||||
Stage 1 | 40 (38.1%) | 6 (35.3%) | 19 (38.7%) | 15 (38.5%) |
Stage 2 | 37 (35.2%) | 5 (29.4%) | 19 (38.7%) | 13 (33.3%) |
Stage 3 | 22 (21%) | 4 (23.5%) | 9 (18.4%) | 9 (23.1%) |
Stage 4 | 6 (5.7%) | 2 (11.8%) | 02 (4.1%) | 2 (5.1%) |